C. Huang

发表

The tumour–stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients

R. Haba, D. Liu, M. Ueno, 2004, British Journal of Cancer.

Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts

C. Huang, G. Yu, L. Ren-Heidenreich, 2014, British Journal of Cancer.

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer.

A. Yamauchi, D. Liu, C. Huang, 2001, The Annals of thoracic surgery.

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

G. Breithardt, H. Crijns, P. Mclaughlin, 2016, Journal of the American Heart Association.

Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC).

D. Gandara, R. Doebele, D. Camidge, 2010 .

Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT

M. Fukushima, H. Wada, D. Liu, 2006, British Journal of Cancer.

Impact of metabolic syndrome on the survival of Chinese patients with resectable esophageal squamous cell carcinoma.

C. Huang, P. Lin, T. Rong, 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway.

C. Huang, L. Liu, S-Q Li, 2018, European review for medical and pharmacological sciences.

Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) (INFORM; C-TONG 0804).

M. Wang, X. Liu, Y. Cheng, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804).

M. Wang, X. Liu, Y. Cheng, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancers

R. Haba, D. Liu, M. Ueno, 2008, British Journal of Cancer.

High Expression of Nuclear Factor of Activated T Cells in Chinese Primary Non-Small Cell Lung Cancer Tissues

S. Shi, F. Zhou, K. Shao, 2007 .

High expression of nuclear factor of activated T cells in Chinese primary non-small cell lung cancer tissues.

Z Chen, S. Shi, F. Zhou, 2007, The International journal of biological markers.

[Combined large cell neuroendocrine carcinoma and squamous cell carcinoma of the lung; report of a case].

D. Masuya, H. Yokomise, M. Gotoh, 2006, Kyobu geka. The Japanese journal of thoracic surgery.